BERWYN, Pa.–(BUSINESS WIRE)–Amring Pharmaceuticals Inc. (Amring), a generic pharmaceutical and ophthalmic medical device company, announced today that it has launched two valued drugs into its generic portfolio and to the U.S. Market:
One is Succinylcholine Chloride Injection, a generic of Quelicin®, launched in April 2019, is used as an adjunct to general anesthesia to facilitate tracheal intubation, and it also provides skeletal muscle relaxation during surgery.
Another is Mesalamine Suppositories, 1000 mg, a generic version of Canasa® Suppositories, an aminosalicylate indicated for the treatment of active ulcerative proctitis.
Both drugs are distributed to retail, hospital, and/or institutional channels allowing Amring to continue adding value to its customers and patients across the U.S.
Daniel Carbery, President and CEO of Amring, said: “We are pleased with our progress so far and are looking forward to our customers realizing the benefits of these products as well the future product development activities in 2019. Amring anticipates adding at least two additional products to its commercial portfolio this year.”